SHR-1701 Combined With Fluzoparib as Maintenance Therapy for Advanced Lung Squamous Cell Carcinoma After Platium Based Chemo-immunotherapy
Latest Information Update: 01 Jan 2024
At a glance
- Drugs Fuzuloparib (Primary) ; Retlirafusp alfa (Primary)
- Indications Carcinoma; Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FLYFLY
- 25 Dec 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 25 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 07 Apr 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.